Chlormadinonacetat Chemische Eigenschaften,Einsatz,Produktion Methoden
R-S?tze Betriebsanweisung:
R60:Kann die Fortpflanzungsf?higkeit beeintr?chtigen.
R61:Kann das Kind im Mutterleib sch?digen.
R40:Verdacht auf krebserzeugende Wirkung.
R48:Gefahr ernster Gesundheitssch?den bei l?ngerer Exposition.
S-S?tze Betriebsanweisung:
S53:Exposition vermeiden - vor Gebrauch besondere Anweisungen einholen.
S22:Staub nicht einatmen.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn m?glich, dieses Etikett vorzeigen).
Beschreibung
Chlormadinone acetate is a synthetic progestin. It binds to progesterone, androgen, and glucocorticoid receptors
in vitro (K
is = 2.5, 3.8, and 16 nM, respectively, for the human receptors). Chlormadinone acetate increases the number of endometrial glands and uterine weight in β-estradiol-primed rabbits when administered at a dose of 45 μg/kg per day for five days. Chlormadinone acetate reduces testosterone-induced increases in the seminal vesicle weight of castrated male rats when administered at doses of 4.6 and 21.5 mg/kg per day for eight days.
Chemische Eigenschaften
Crystalline Solid
Weltgesundheitsorganisation (WHO)
Chlormadinone acetate, a synthetic progestogen, was introduced
in 1965 as a component in oral contraceptive preparations. In 1967, as a result of
new regulations required by the United States Food and Drug Administration,
chlormadinone acetate was submitted to long-term toxicity studies and by the early
1970s it was shown to be associated with an increased incidence of mammary
tumours in beagle bitches which led to its withdrawal by several regulatory
authorities. Subsequently the validity of the beagle bitch model as a predictor of
carcinogenicity of steroid contraceptives has been contested by many national
regulatory authorities and chlormadinone remains available in some countries for
contraceptive purposes. In some instances it is indicated for treatment of
progesterone deficiency and endometriosis, and of irregular uterine bleeding due
to fibroids.
(Reference: (WHODI) WHO Drug Information, 84.1, 5, 1984)
Sicherheitsprofil
Suspected carcinogen
with experimental carcinogenic and
tumorigenic data. Moderately toxic by
intraperitoneal route. Human maternal and
reproductive effects by ingestion,
intramuscular, and possibly other routes:
ovary, uterus, cervix, vagina, and fallopian
tube changes; menstrual cycle changes or
disorders; changes in ferthty; and other
unspecified female effects. A human
teratogen that causes developmental
abnormalities of the endocrine system in the
fetus. Experimental teratogenic and
reproductive effects. An oral contraceptive.
When heated to decomposition it emits
toxic fumes of Cl-.
Chlormadinonacetat Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte